by April Breyer Menon | Jun 9, 2017
Download PDF
by April Breyer Menon | Feb 1, 2017
The Federal Circuit is not afraid to call to task the Patent Trial and Appeal Board when it comes to potential procedural breaches. Justin Oliver and Kathryn Easterling review relevant cases. Download PDF
by April Breyer Menon | Jul 7, 2016
On July 5, 2016, the Federal Circuit issued a decision interpreting the 180-day-notice-of-first-commercial-marketing provision of the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”). Amgen Inc. v. Apotex Inc. (Amgen II), No. 2016-1308 (Fed. Cir. July...
by April Breyer Menon | Apr 6, 2015
It has been five years to the month since the Biologics Price Competition and Innovation Act (“BPCIA”) was signed into law, and March 2015 was the busiest month to date for the emerging U.S. biosimilars market. Currently worth approximately $1 billion a year...